Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,628
datasets available to search
ShareScore release 0.9.0
Dataset results
1,628 results for “type safety”
Blood glucose modulation and safety of efferent vagus nerve stimulation in a type 2 diabetic rat model
Open the record for dataset details and reuse information.
Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials
<p class="CxSpFirst"><b>Context:</b> Variations in the prevalence and aetiology of type 2 diabetes (T2D) across race and ethnicity may affect treatment responses. Semaglutide is a glucagon-like peptide-1 (GLP-1) analog approved for once–weekly, subcutaneous (s.c.) treatment of T2D.</p> <p class="CxSpFirst"><b>Objective:</b> To compare semaglutide efficacy and safety in race and ethnicity subgroups across the SUSTAIN trials.</p> <p class="CxSpMiddle"><b>Design:</b> <i>Post hoc </i>analysis of data from phase 3 randomized SUSTAIN 1–5 and 7 (pooled) and SUSTAIN 6 trials.</p> <p class="CxSpMiddle"><b>Participants:</b> 3,074 subjects (SUSTAIN 1–5 and 7); 1,648 subjects (SUSTAIN 6).</p> <p class="CxSpMiddle"><b>Interventions:</b> Semaglutide 0.5 or 1.0 mg, placebo or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine 100IU/ml and dulaglutide 0.75 or 1.5 mg).</p> <p class="CxSpFirst"><b>Main Outcome Measures:</b> Change in HbA<sub>1c</sub> and body weight from baseline to week 30/40/104, other efficacy and safety endpoints.</p> <p class="CxSpMiddle"><b>Results:</b> HbA<sub>1c</sub> was reduced from baseline by 1.0–1.5%-points and 1.3–2.0%-points, and body weight by 2.3–4.7 kg and 3.6–6.1 kg with semaglutide 0.5 and 1.0 mg, respectively, across race and ethnicity subgroups. Minor changes in blood pressure and lipid profiles were observed. Adverse events (AEs) were reported in similar proportions of subjects across trials. More Asian vs other race subgroups discontinued treatment prematurely due to AEs. The most commonly reported AEs were gastrointestinal disorders.</p> <p class="CxSpMiddle"><b>Conclusion(s):</b> In this SUSTAIN trials <i>post hoc</i> analysis, semaglutide was associated with consistent and clinically relevant reductions in HbA<sub>1c</sub> and body weight in subjects with T2D, with minor variations in efficacy and safety outcomes associated with race or ethnicity.</p>
Comparative Efficacy and Safety of Sitagliptin Phosphate Combined with Gliclazide Sustained-Release Tablets Versus Metformin in Treatment-Naïve Patients with Type 2 Diabetes Mellitus and Glucotoxicity: A Single-Center, Prospective, Randomized Controlled Non-Inferiority Study
<p>This dataset supports the manuscript titled "Comparative Efficacy and Safety of Sitagliptin Phosphate Combined with Gliclazide Sustained-Release Tablets Versus Metformin in Treatment-Naïve Patients with Type 2 Diabetes Mellitus and Glucotoxicity: A Single-Center, Prospective, Randomized Controlled Non-Inferiority Study." The study aims to compare the efficacy and safety of sitagliptin phosphate combined with gliclazide sustained-release tablets against metformin in treatment-naïve patients with type 2 diabetes mellitus and glucotoxicity. Data include clinical measurements, laboratory test results, and adverse event records collected throughout the trial period. Statistical analyses were conducted to assess non-inferiority between the two treatment groups. This dataset provides valuable insights for researchers interested in diabetes management, pharmacotherapy, and randomized controlled trials.</p>
Exothermal data from thermal safety assessment of type 21700 lithium-ion batteries with NMC, NCA and LFP cathodes by means of Accelerating Rate Calorimetry (ARC)
<p>Data of safety investigation and thermal abuse behavior of commercial type 21700 LIB cells is provided.</p> <p>It has been acquired with Accelerating Rate Calorimetry (ARC), using a Thermal Hazard Technology type ES ARC.</p> <p>Moreover, thermal abuse was done by means of the so-called Heat-Wait-Seek (HWS) test, at different states of charge (SOC) from 0 to 100.</p> <p>Different cathode chemistries are compared (NMC, NCA and LFP), as well as for NCA chemistry, the high energy (HE) and high power (HP) cell design.</p> <p>For each cell, data includes the exothermal behavior of the cells, which is recorded only when the cell is behaving exothermally in the ARC, above a threshold of 0.02 °C / min.</p> <p>Hence, in the files, time in minutes, temperature on the surface at the center of the cell in °C and the registered temperature rate in °C / min is provided. Cathode chemistry, as well as SOC, is indicated in the file name, each set of parameters has been tested at least twice with another cell, which is indicated with M and consecutive numbering of the test number.</p> <p>This data is supporting this article in the journal Batteries:</p> <p><a href="https://doi.org/10.3390/batteries9050237">https://doi.org/10.3390/batteries9050237</a></p> <p>Additional supporting material to this article are the maximum temperatures for thermal abuse, that are published here:</p> <p><a href="https://doi.org/10.5281/zenodo.7867730">https://doi.org/10.5281/zenodo.7867730</a></p> <p> </p> <p> </p>
Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)
ClinicalTrials.gov study NCT05532813. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy
ClinicalTrials.gov study NCT00515632. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)
ClinicalTrials.gov study NCT02059161. IPD Sharing: YES. Countries: 0. Publications: 1.
Efficacy and Safety of Weight-Based Insulin Titration Regimen in Hospitalized Patients With Type 2 Diabetes
ClinicalTrials.gov study NCT03220919. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus
ClinicalTrials.gov study NCT04075110. IPD Sharing: YES. Countries: 1. Publications: 1.
Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
ClinicalTrials.gov study NCT04356742. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive
ClinicalTrials.gov study NCT00800683. IPD Sharing: Not stated. Countries: 6. Publications: 1.
Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes
ClinicalTrials.gov study NCT04943692. IPD Sharing: NO. Countries: 1. Publications: 28.
Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes
ClinicalTrials.gov study NCT00110240. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes
ClinicalTrials.gov study NCT01497522. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Placebo-Controlled Clinical Nutrition Study of the Safety and Metabolic Effects of Two Medical Foods in Type 2 Diabetes
ClinicalTrials.gov study NCT03893422. IPD Sharing: NO. Countries: 1. Publications: 1.
Observational Study to Observe the Safety of Levemir® Treatment in Children and Adolescents With Type 1 Diabetes
ClinicalTrials.gov study NCT00704574. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency
ClinicalTrials.gov study NCT00616811. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin
ClinicalTrials.gov study NCT00324363. IPD Sharing: Not stated. Countries: 4. Publications: 2.
Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine
ClinicalTrials.gov study NCT01636245. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Trigeminal Neuralgia. Safety Issues.
ClinicalTrials.gov study NCT02662972. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.